Autologous Serum Eye Drops In The Management Of Limbal Stem Cell Deficiency Associated With Glaucoma Surgery

Published 2022 - 40th Congress of the ESCRS

Reference: PO325 | Type: Free paper | DOI: 10.82333/jfjw-vf40

Authors: Clemence Bonnet* ¹ , Sophie X. Deng ²

¹Cornea,Cochin Hospital,Paris,France;Cornea,Stein Eye Institute,Los Angeles,United States, ²Cornea,Stein Eye Institute,Los Angeles,United States

Purpose

To evaluate safety and efficacy of autologous serum eye drops (AS) in the treatment of limbal stem cell deficiency (LSCD) associated with glaucoma surgery.

Setting

Retrospective monocentric case series.

Methods

Retrospective case series of eyes with glaucoma surgery-induced LSCD treated with AS. Diagnosis of LSCD was confirmed by anterior segment optical coherence tomography, in vivo confocal microscopy and/or impression cytology. LSCD severity was staged using a clinical scoring system (2-10 points). Outcome measures were changes (≥ 2 points) of the LSCD score and best corrected visual acuity (BCVA) from the baseline to the last follow-up.

Results

Thirteen eyes of 12 consecutive patients treated with 50% AS for at least 3 months were included. The mean age was 78.9±7.5 years and the mean duration of AS use was 20.9±16.8 months. Indications of AS included LSCD progression in 8 eyes (61.5%) and visual axis threatening in 5 eyes (38.5%). The mean LSCD score at baseline (6.7±1.6) was similar to that at last follow-up (6.5±2.2, p=0.625). Two eyes (15.4%) showed improvement, 9 eyes (69.2%) were stable, and 2 eyes (15.4%) worsened. The mean baseline BCVA (0.89±0.64 logMAR) was similar to the mean final BCVA (1.05±0.63 logMAR, p=0.173). There were no serious adverse complications related to AS.

Conclusions

This case series shows that AS is well tolerated and may stabilize the progression of LSCD with limited effects. A larger study is necessary to confirm the findings.